Immune cell injection takes on Hard-to-Treat leukemia

NCT ID NCT06234904

Recruiting now Disease control Sponsor: Imbioray (Hangzhou) Biomedicine Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jul 02, 2026 · Last updated Jul 02, 2026

Summary

This early-stage trial tests an experimental cell therapy called IBR733 for adults with acute myeloid leukemia (AML) that has returned or not responded to standard treatment. The therapy involves giving immune cells by vein in repeated cycles. The main goals are to check safety, find the best dose, and see if the treatment can shrink or clear the leukemia.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IBR733 cell injection (immune cells given by IV)
What this could lead to: If safe and effective, this could point toward a new cell-based treatment option for people with hard-to-treat acute myeloid leukemia.
What could go wrong: This is an early, small Phase 1 trial focused on safety, not proof of cure. The treatment may cause side effects or fail to control the leukemia.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE MYELOID LEUKEMIA

Contacts and locations

Locations

The First Affiliated Hospital of Soochow University
RECRUITING

Suzhou, Jiangsu, 215006, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.